Archive for the ‘research’ Category

Acute Psychosis After COVID Shot, Moderna Booster Singled Out for Chronic Hives, Merck COVID Drug Linked to New Virus Mutations

https://petermcculloughmd.substack.com/p/acute-psychosis-after-covid-19-vaccination

Acute Psychosis after COVID-19 Vaccination

Alarming Manuscripts Report Acute Neuropsychiatric Symptoms

Peter A. McCullough, MD, MPH™

By Peter A. McCullough, MD, MPH

Unvaccinated patients have mentioned half-jokingly that COVID-19 vaccination in friends and family makes some of them “crazy.” While I have always brushed this off as fear driven vaccine ideology taking over common sense in some zealots, the building literature on neuropsychiatric symptoms is alarming. There are now ~10 papers describing headache, fever, and a range of acute neuropsychiatric symptoms after both mRNA and adenoviral COVID-19 vaccination. The strong bias among editors and publishers has kept countless papers out of the mainstream medical media, hence one has to look far and wide to find information on the topic of vaccine safety. Borovina et al, from Croatia described three cases of acute headache followed by psychosis.  (See link for article and study)

_______________

Important excerpt:

One of the cases progressed to attempted suicide with a knife stabbing to the abdomen requiring emergency abdominal surgery.

As a doctor I am disturbed by medical evidence demonstrating gene coded SARS-CoV-2 Wuhan Institute of Virology Spike protein in the human brain after vaccination. I wonder how many subtle changes go clinically unrecognized.

McCullough rightly states that every suicide after Dec. 2020 should be investigated and the brand, doses, and dates of “vaccination” should be recorded and noted.  Unfortunately, none of this will happen.  It’s all #ABV (anything but the vaccine).

For more:

_________________

https://www.medpagetoday.com/infectiousdisease/covid19vaccine/102923

Moderna Booster Vaccine Singled Out for Chronic Hives

— Chronic spontaneous urticaria more frequent when compared with Pfizer’s mRNA vaccine

by Elizabeth Short, Staff Writer, MedPage Today February 1, 2023

A photo of a vial of the Spikevax COVID vaccine

The monovalent Moderna COVID-19 booster vaccine may be associated with an elevated risk for new-onset chronic spontaneous urticaria (CSU), or hives lasting more than 6 weeks, according to a Swiss study.

Among people who got an mRNA COVID vaccine booster and had new-onset hives reported to local allergists, 90% had vaccination precede CSU in the canton of Vaud during the study period, as did 81% of patients in the nationwide cohort, reported Yannick Daniel Muller, MD, PhD, of the University of Lausanne in Switzerland, and coauthors.  (See link for article)

_______________

**Comment**

Predictably, the authors still want everyone to get “vaccinated,” and take the safe route by stating more research is needed.  They state that Moderna shots contain higher doses of mRNA and are more immunogenic than Pfizer shots, although both are clearly linked to a multitude of adverse events and death. The Vaccine advisory committee unanimously endorsed the FDA’s plan to harmonize the primary and booster shots to contain a bivalent composition with components targeting BA.4/5 and the original SARS-CoV-2 strain, eliminating the original monovalent products.  Both are deplorable and useless.

________________

https://www.bloomberg.com/news/articles/2023-02-01/merck-s-mrk-covid-drug-linked-to-viable-spreading-mutants-study-says

Merck Covid Drug Linked to New Virus Mutations, Study Says

  • So far, new versions aren’t more lethal, immune-evasive
  • Merck disputes study’s claim, says drug is ‘valuable’
Lagevrio
Lagevrio  Photographer: Donato Fasano/Getty Images
Article Summary:
  • Preprint study found here
  • The study points out the risk of trying to alter the pathogen’s genetic code
  • The study found that the medication molnupiravir (Lagevrio) is giving rise to new mutations in some patients which has some researchers worried the drug may create more contagious or dangerous variations of COVID
  • One author of the study states the drug should be discontinued due to the risks

No Testing Required to Get Paxlovid & Molnupiravir/Lagevrio, Even Though They Are Dangerous

But in a slick move, the FDA has removed COVID testing requirements to make it even easier to obtain Pfizer (Paxlovid) and Merck (Molnupiravir/Lagevrio) COVID treatments.  Now, exposed individuals with signs and symptoms (that look like any other flu-bug), can simply waltz into their doctor’s office and be diagnosed with COVID, even if they have a negative test result: however, they still can not obtain cheap, safe, effective drugs like ivermectin, HCQ, or even vitamin C.

And low and behold, a new study finds that ivermectin is a promising cancer drug.

This should tell you everything you need to know.

Abstract

Ivermectin is a widely used antiparasitic drug and shows promising anticancer activity in various cancer types. Although multiple signaling pathways modulated by ivermectin have been identified in tumor cells, few studies have focused on the exact target of ivermectin. Herein, we report the pharmacological effects and targets of ivermectin in prostate cancer. Ivermectin caused G0/G1 cell cycle arrest, induced cell apoptosis and DNA damage, and decreased androgen receptor (AR) signaling in prostate cancer cells. Further in vivo analysis showed ivermectin could suppress 22RV1 xenograft progression. Using integrated omics profiling, including RNA-seq and thermal proteome profiling, the forkhead box protein A1 (FOXA1) and non-homologous end joining (NHEJ) repair executer Ku70/Ku80 were strongly suggested as direct targets of ivermectin in prostate cancer. The interaction of ivermectin and FOXA1 reduced the chromatin accessibility of AR signaling and the G0/G1 cell cycle regulator E2F1, leading to cell proliferation inhibition. The interaction of ivermectin and Ku70/Ku80 impaired the NHEJ repair ability. Cooperating with the downregulation of homologous recombination repair ability after AR signaling inhibition, ivermectin increased intracellular DNA double-strand breaks and finally triggered cell death. Our findings demonstrate the anticancer effect of ivermectin in prostate cancer, indicating that its use may be a new therapeutic approach for prostate cancer.

Well now, ‘the powers that be’ simply can not have this.
Better censor and ban it off the face of the earth.

Category:

Activism, Psychological Aspects, research, Treatment, vaccines, Viruses

Patient Contracts Babesia From a Blood Donor: Only 14 States Test For It

https://danielcameronmd.com/patient-contracts-babesia-blood-donor/

PATIENT CONTRACTS BABESIA FROM A BLOOD DONOR

babesia-blood-donor

Babesia is most commonly transmitted through a tick bite but it can also be transmitted through a blood transfusion. To minimize the risk to the public, blood banks now screen donors for Babesia in endemic states.

By 

In their article “Transfusion-transmitted babesiosis in a patient with sickle cell disease undergoing chronic red cell exchange,” Costa and colleagues describe a patient who contracted Babesia from a donor living in Ohio, a state that is not considered endemic for Babesia.¹

According to the authors, a 30-year-old man with sickle cell disease (SCD) required approximately 10 units of red blood cells every 3–4 weeks throughout his childhood.

Approximately 2 months after a red blood cell exchange, he presented with fever, neck pain, and photophobia. Several days later, he developed a persistent fever, chills, headache, fatigue, and loss of appetite.

He was diagnosed with Babesia through identification of parasites in his red blood cells and positive antibodies. He was also borderline positive on an antibody test for Anaplasma phagocytophilum and Ehrlichia chaffeensis.

“Prior to laboratory-based blood donor screening for Babesia, transfusion-transmitted babesiosis (TTB) was a leading infectious risk to the blood supply in the United States.”

The young man was treated for Babesia with azithromycin and atovaquone for 10 days with resolution of his symptoms. He was not treated for Anaplasma phagocytophilum or Ehrlichia chaffeensis.

The patient lived in a state endemic for Babesia but did not recall a tick bite.

“A donor lookback investigation was initiated with the blood supplier,” the authors wrote. They found that in the preceding 6 months, the patient had received 65 units of blood, with 58 units screened for Babesia.

Unfortunately, “One of the donors of the 7 untested units was B. microti seropositive,” the authors wrote. The donor lived in a state not requiring Babesia screening.

“Our case demonstrates the continued vulnerability of the US blood supply to Babesia.”

“The seropositive donor had not had any symptoms of babesiosis; he lived in Ohio and reported being very active over the past year, including hiking and camping in several states (Ohio, Tennessee, and North Carolina),” the authors wrote.

In 2019, the FDA recommended testing of blood donors for Babesia in the 14 states where almost all cases of Babesia have been reported. “The policy confined to 14 states (Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, Wisconsin),” wrote the authors.

Authors Conclude:

“Heightened awareness and health care provider education are imperative, especially in non-endemic [states] where clinicians may not be accustomed to diagnosing community-acquired or TTB, placing transfusion recipients at risk of delayed diagnosis and severe disease.

References:
  1. Costa V, Mercure-Corriveau N, Gourneau J, et al. Transfusion-transmitted babesiosis in a patient with sickle cell disease undergoing chronic red cell exchange. Transfusion. Jan 13 2023;doi:10.1111/trf.17244

________________

**Comment**

Once again, the madness of limiting potential infection to certain geographical areas despite the ability of people, animals, and bugs to move around is completely asinine.  Yet, here we are – still in the madness.

For more:

Category:

Babesia, research, Testing, Treatment

The Many Presentations of the Lyme Disease rash

https://danielcameronmd.com/many-presentations-lyme-disease-rash/

THE MANY PRESENTATIONS OF THE LYME DISEASE RASH

lyme-disease-rash

The general public, as well as practicing clinicians often believe that the rash indicative of Lyme disease always presents in a bull’s-eye pattern. This is not correct. In this study, investigators sought to characterize various presentations of the rash in Lyme disease patients, in an effort to assist clinicians in recognizing the broad spectrum of EM lesions.

By 

In the study “The Spectrum of Erythema Migrans in Early Lyme Disease: Can We Improve Its Recognition?,” investigators examined images of lesions from 69 participants, including 43 men and 26 women, suspected to have early Lyme disease.  The majority of participants (83%) presented with a single lesion.¹

The images were retrospectively evaluated by a dermatologist and a family practitioner with expertise in early Lyme disease.

The authors found that 35 lesions (51%) were erythema migrans (EM); 23 lesions (30%) were considered to be possible early EM or tick bite reactions, and 11 (16%) were thought not to be EM, but rather other diagnoses, including ringworm, allergic contact dermatitis, and mosquito bites.

“Only two lesions (6%) were observed with a classic bull’s eye or ring-within-a-ring pattern.”

EM rashes were reported most frequently to appear on the abdomen, thigh, back and hip.

Participants with an EM rash reported the following symptoms: chills, fever, night sweats, headache, fatigue, body aches, nausea and neuralgia.

Most EM lesions appeared:

  • Uniform (51%)
  • Pink (74%)
  • With an oval shape (63%)
  • Well-defined borders (92%)

What did early EM or tick bite reactions look like? They “were typically <5 cm in size (74%), red (52%), round lesions (61%), with a punctum present (100%),” according to the authors.

Lesions that were not EM rashes appeared: pink or red (64%), round (55%), or uniform (45%) lesions, but also had raised (25%) or irregular borders (33%).

“EM commonly occurs in forms that are not the classic bull’s eye.”

“Only 14 (20%) participants overall had positive laboratory evidence for LD; these included 13 (37%) of the participants with EM-classified lesions,” the authors wrote.

VIEW PHOTOS OF EM RASHES

The authors suggest that “education should deemphasize the bull’s eye form and stress the wide variability in EM instead and the fact that many of them present as a uniform, homogeneous lesion.”

The authors conclude:

  • “Patients often present with lesions that may represent the very early stage of EM or tick bite reactions, and most patients will test negative on currently available laboratory tests…”
  • “Clinicians may not be aware of all existing variations, such that some LD patients with EM may not be immediately recognized and promptly diagnosed and treated. Hence, further improvements in terms of clinician awareness and recognition of EM are needed.”
Related Articles:

What does a Lyme disease rash look like?

Lyme disease rash puzzles doctors, leads to misdiagnoses

Erythema migrans rash doesn’t always have Bull’s eye appearance

References:
  1. Schotthoefer A M, Green C B, Dempsey G, et al. (October 25, 2022) The Spectrum of Erythema Migrans in Early Lyme Disease: Can We Improve Its Recognition? Cureus 14(10): e30673. doi:10.7759/cureus.30673

________________

For more:

Category:

Lyme, research

A High Quality Ixodes Scapularis Genome Advances Tick Science

https://www.nature.com/articles/s41588-022-01275-w

Published: 

A high-quality Ixodes scapularis genome advances tick science

Nature Genetics (2023)

Abstract

Ixodes spp. and related ticks transmit prevalent infections, although knowledge of their biology and development of anti-tick measures have been hindered by the lack of a high-quality genome. In the present study, we present the assembly of a 2.23-Gb Ixodes scapularis genome by sequencing two haplotypes within one individual, complemented by chromosome-level scaffolding and full-length RNA isoform sequencing, yielding a fully reannotated genome featuring thousands of new protein-coding genes and various RNA species. Analyses of the repetitive DNA identified transposable elements, whereas the examination of tick-associated bacterial sequences yielded an improved Rickettsia buchneri genome. We demonstrate how the Ixodes genome advances tick science by contributing to new annotations, gene models and epigenetic functions, expansion of gene families, development of in-depth proteome catalogs and deciphering of genetic variations in wild ticks. Overall, we report critical genetic resources and biological insights impacting our understanding of tick biology and future interventions against tick-transmitted infections.

_______________

**Comment**

I hate to be the bearer of bad news, but this sudden concern about tick genomes is all due to the mad gold-rush on mRNA products that are the new popular trend every researcher vying for government grants is seeking today, including industry, governmental, and educational institution tick researchers. You see, by doing innocuous-seeming research on genomes. genetically altered organisms (GMOs), and “climate change,” – they can continue to get paid and keep their labs running like a well-oiled machines, despite the very real impact on the environment – including humans.  After all, researchers are smart people and clearly understand that if you study things like contaminants in vaccines, your lab gets shut down and your position gets terminated.  Doctors are told to “zip it” regarding vaccine injury or their licenses are suspended. You essentially get “Wakefielded,” and life as you know it changes forever.

Few people are willing to swallow that red pill.

It’s far easier to just give The Cabal what they want and refrain from making any waves.

This is why ZERO transmission studies regarding Lyme/MSIDS have been done in decades.  It’s why mainstream research will never admit in a million years that Lyme/MSIDS is persistent. They simply don’t want that Pandora’s box opened or even questioned.  Better to continue using nearly 40 year old research showing the potential of transmission but declaring it doesn’t exist due to some arbitrary cut-off made for a pre-determined outcome.

Our corrupt public health agencies have been declaring things for a long time.

Despite the absolute flop of the COVID mRNA gene–therapy injections, the massive numbers of sudden deaths (SADS), heart issues, and other life-altering adverse reactions, the mRNA platform is being forced down our throats, like it or not, – despite experts warning, indeed shouting, that it is unstable, untested and unsafe.  It doesn’t even work well, but The Cabal simply changes definitions, manipulates thresholds, waives normal testing requirements, hides and recategorizes data, and then rubber stamps approval.

Hey, when you’re in charge, you can seemingly do whatever you want.

Category:

research, Ticks

Study: Controlled Burns Reduce Ticks, Lyme Disease

https://www.bayjournal.com/news/wildlife_habitat/study-controlled-burns-reduce-ticks-lyme-disease/article

Study: Controlled burns reduce ticks, Lyme disease

By Ad Crable

Jan. 13, 2023

Prescribed fire

A prescribed fire takes place at the Arboretum at Penn State. (Courtesy of the Arboretum at Penn State)

As tick-borne Lyme disease continues to spread in Pennsylvania and other Chesapeake Bay drainage states, a new study suggests more use of prescribed burns on public and private forests could help reduce both the numbers of ticks and incidence of the disease.

In a paper published in Ecological Applications, researchers from Penn State, the U.S. Forest Service and New Jersey Department of Environmental Protection said the increased use of prescribed fire by forest managers to control invasive plants, improve wildlife habitat and restore ecosystem health can also help knock down the tick problem.  (See link for article)

________________

**Comment**

For more:

    Category:

    Lyme, Prevention, research, Ticks